Findings from a multicenter, randomized, placebo-controlled, phase III study have demonstrated the beneficial effects of the 5-hydroxytryptamine 4 receptor agonist, prucalopride, for chronic ...

(ANIP), a biopharmaceutical company, on Thursday announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Prucalopride Tablets, the generic ...